Development of cancer cells that are an infrequent but dangerous byproduct of gene therapy can now be reduced.
Grant Trobridge, an associate professor of pharmaceutical sciences, has altered the way a virus carries a beneficial gene to its target cell. The modified viral vectors reduce the risk of cancer and can be used for many blood diseases.
Gene Therapy - New Hope for Treating Niemann-Pick Disease Type C1
Niemann-Pick disease can be treated by correcting the faulty NPC1 gene using gene therapy.
Advertisement
‘A vector developed from a foamy retrovirus is used in gene therapy to treat SCID-X1 by replacing defective genes with repaired ones.’
Tweet it Now
Trobridge and his team report their development in Scientific Reports, an online open-access journal produced by the Nature Publishing Group. The team is translating their findings into a stem cell gene therapy to target a life-threatening immunodeficiency in newborns called SCID-X1, also known as "Boy in the Bubble Syndrome."
Gene therapy holds potential for treating genetic diseases by replacing defective genes with repaired ones. It has shown promise in clinical trials but has also been set back by difficulties delivering genes, getting them to work for a long time and safety issues. A joint French and English trial, for example, successfully treated 17 out of 20 patients with SCID-X1 only to see five of them develop leukemia.
![Gene Therapy For Blistering Skin Disease Shows Promise]( "Gene Therapy For Blistering Skin Disease Shows Promise")
Patients with blistering skin disease, epidermolysis bullosa, who received skin grafting for open wounds,, responded well to treatment and found it to be safe.
Trobridge and his colleagues are using a vector developed from a foamy retrovirus, so named because it appears to foam in certain situations. Unlike other retroviruses, they don't normally infect humans. They also are less prone to activate nearby genes, including genes that might cause cancer.
Retroviruses are a natural choice for gene therapy because they work by inserting their genes into a host's genome. With an eye toward making the vector safer, the Trobridge team altered it to change how it interacts with a target stem cell so it would insert itself into safer parts of the genome. They found that it integrated less often near potential cancer-causing genes.
"Our goal is to develop a safe and effective therapy for SCID-X patients and their families," said Trobridge. "We've started to translate this in collaboration with other scientists and medical doctors into the clinic." He predicted that the therapy could be ready for clinical trials within five years.
Source: Eurekalert
Gene Therapy For Blistering Skin Disease Shows Promise
Patients with blistering skin disease, epidermolysis bullosa, who received skin grafting for open wounds,, responded well to treatment and found it to be safe.
Advertisement
Trobridge and his colleagues are using a vector developed from a foamy retrovirus, so named because it appears to foam in certain situations. Unlike other retroviruses, they don't normally infect humans. They also are less prone to activate nearby genes, including genes that might cause cancer.
Retroviruses are a natural choice for gene therapy because they work by inserting their genes into a host's genome. With an eye toward making the vector safer, the Trobridge team altered it to change how it interacts with a target stem cell so it would insert itself into safer parts of the genome. They found that it integrated less often near potential cancer-causing genes.
"Our goal is to develop a safe and effective therapy for SCID-X patients and their families," said Trobridge. "We've started to translate this in collaboration with other scientists and medical doctors into the clinic." He predicted that the therapy could be ready for clinical trials within five years.
Source: Eurekalert
Gene Therapy Against Aging Found to be Successful
The first successful gene therapy in a human increases telomere length and lowers biological age by 20 years.
Advertisement
 Gene Therapy Brings Hope for Bubble Boy Disease TreatmentGene therapy by GlaxoSmithKline offers hope for children with bubble boy disease with Phase I and II approved by EU regulation board. | Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
Chronotherapy (the sleep-wake cycle) is observed as a valuable alternative treatment in cancer diagnosis and treatment.
A nanoengineering platform targets neutrophils, the white blood cells without killing pancreatic cancer cells paving the way for effective treatments.
The survival rates between lobectomy and wedge resection surgical procedures were found to be the same among lung cancer patients.
The mechanism by which the kinases cause inflammation has been discovered by scientists.
Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.